Neuphoria Therapeutics Income Statement (2021-2025) | NEUP

Income Statement Dec2021 Jun2023 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue -0.30M0.66M15.00M-0.01M
Operating items
Research & Development 1.90M1.74M1.62M3.75M3.79M0.70M
Selling, General & Administrative 1.67M2.63M1.41M2.07M1.87M2.13M
Other Operating Expenses 1.24M
Operating Expenses 3.57M4.37M3.02M5.82M5.65M4.06M
Operating Income -3.57M-3.70M11.98M-5.84M-5.65M-4.06M
EBIT -3.57M-3.70M11.98M-5.84M-5.65M-4.06M
Non-operating items
Interest & Investment Income 0.04M0.03M0.01M0.09M0.14M0.17M
Other Non Operating Income 2.87M0.81M-0.98M-3.12M-4.37M5.38M
Non Operating Income 2.63M1.77M-0.80M-3.32M-4.29M5.89M
Net income details
EBT -0.94M-1.93M11.18M-15.42M-9.94M1.83M
Tax Provisions -0.13M-0.01M-0.08M-0.27M-0.03M0.03M
Profit After Tax -0.80M-1.94M11.30M-8.91M-9.91M1.86M
Income from Continuing Operations -0.80M-1.92M11.26M-15.16M-9.91M1.79M
Consolidated Net Income -0.80M-1.92M11.26M-15.16M-9.91M1.79M
Income towards Parent Company -0.80M-1.92M11.26M-15.16M-9.91M1.79M
Net Income towards Common Stockholders -0.80M-1.92M11.26M-15.16M-9.91M1.79M
Additional items
EPS (Basic) -0.62-1.236.55-9.34-4.410.41
EPS (Weighted Average and Diluted) -0.62-1.796.55-9.34-4.41-0.77
Shares Outstanding (Weighted Average) 156.08M981.64M1.30M1.58M1.72M1.62M2.25M4.54M
Shares Outstanding (Diluted Average) 981.64M1.30M1.58M1.72M1.62M2.25M4,536.23M
EBITDA -0.22M3.23M11.07M-7.82M-9.86M2.43M
Tax Rate 14.11%0.60%-0.73%1.73%0.35%1.90%